Crinetics stocks surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech companyin a deal valued at approximately $10 billion.
